WallStSmart

Check-Cap Ltd. (MBAI)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MBAI leads profitability with a 0.0% profit margin vs -9.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).

MBAI

Avoid

28

out of 100

Grade: F

Growth: 4.3Profit: 5.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -29.22

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.8
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MBAI3 strengths · Avg: 10.0/10
P/E RatioValuation
2.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
120.5%10/10

Every $100 of equity generates 120 in profit

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

NTRA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
38.8%10/10

Revenue surging 38.8% year-over-year

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Areas to Watch

MBAI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.67M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

NTRA4 concerns · Avg: 3.3/10
Price/BookValuation
17.3x4/10

Trading at 17.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-12.8%2/10

ROE of -12.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MBAI

The strongest argument for MBAI centers on P/E Ratio, Return on Equity, Debt/Equity.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.

Bear Case : MBAI

The primary concerns for MBAI are Revenue Growth, EPS Growth, Market Cap.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

MBAI profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.54 — expect wider price swings.

NTRA is growing revenue faster at 38.8% — sustainability is the question.

NTRA generates stronger free cash flow (18M), providing more financial flexibility.

Bottom Line

NTRA scores higher overall (31/100 vs 28/100) and 38.8% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Check-Cap Ltd.

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company is headquartered in Isfiya, Israel.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?